{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Total abstinence if it is the preferred and constant lifestyle of the subject. Thus,', 'periodic abstinence such as ovulation, symptothermal, postovulation, calendar', 'methods, and withdrawal are not acceptable methods of contraception.', 'Male sterilization surgery: at least 6 months prior to the first dose of study treatment', 'in the core study (with the appropriate postvasectomy documentation of the absence', 'of sperm in the ejaculate). For female subjects, the vasectomized male should be the', 'only partner.', 'Placement of established intrauterine device (IUD): IUD copper or IUD with', 'progesterone', 'Barrier method (condom and intravaginal spermicide, cervical caps with spermicide,', 'or diaphragm with spermicide) in combination with the following: established oral,', 'injected, or implanted hormone methods of contraception or contraceptive patch', '7. Subject is unwilling or unable to follow the procedures outlined in the protocol', '8. Other medical or psychiatric conditions, or laboratory abnormalities that may increase the', 'potential risk associated with study participation and administration of the study', \"treatment, or that may affect study results interpretation and, as per Investigator's\", 'judgement, make the subject ineligible.', '5.3.3', 'Subject Restrictions', \"The following restrictions may affect a subject's ability to participate in this study:\", 'Availability to attend visits according to the protocol within the allowed window', 'period specified in Table 1', 'Ability to perform self-administration of study treatment, availability of caregiver to', 'administer study treatment, or ability to visit study site to administer study treatment', 'Concomitant medication restrictions as described in Section 6.13', 'Fasting (water and concomitant medications are permitted) for at least 9 hours prior to', 'all study visits', 'The Investigator (or designee) should review these restrictions with the subject when', \"assessing eligibility to determine any potential challenges in the subject's ability to comply\", 'with the protocol. Subjects not able to comply with the above mentioned restrictions should', 'not be enrolled into the study.', 'Amendment 2: 06 March 2019', '55', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5.3.4', 'Premature Subject Withdrawal', 'All subjects are free to withdraw from participation in the study at any time, for any reason,', 'specified or unspecified, and without prejudice to further treatment.', 'If premature withdrawal occurs for any reason, the Investigator must make every effort to', \"determine the primary reason for a subject's premature withdrawal from the study and record\", 'this information on the source documents and appropriate electronic case report form', '(eCRF).', 'Subjects will be completely withdrawn from study treatment and all assessments in the', 'following cases:', 'Withdrawal of informed consent', 'Death of subject', 'Subject lost to follow-up', '- Note: If the subject is lost to follow-up, the Investigator should attempt to contact', 'the subject until the last scheduled Safety Follow-Up Visit. The date of study', 'termination for the subject is the date of last contact with subject.', 'If the subject withdraws from the study and withdraws consent for disclosure of future', 'information, no further evaluations should be performed, and no additional data should be', 'collected. R-Pharm International may retain and continue to use any data collected before', 'such withdrawal of consent.', 'Investigators are strongly encouraged to discuss the withdrawal of a subject with R-Pharm', \"International or R-Pharm International's designee in advance whenever possible.\", '5.4', 'Study Procedures', 'Every effort should be made to ensure that the protocol-required tests and procedures are', 'completed as described. However, it is anticipated that from time to time there may be', 'circumstances outside of the control of the Investigator that may make it unfeasible to', 'perform the test. In these cases, the Investigator will take all steps necessary to ensure the', 'safety and wellbeing of the subject.', 'The timing for all study visits during the open-label Treatment Period is relative to', 'OLE Baseline. The timing for all study visits during the Safety Follow-Up Period', '(Visits SFU-1, SFU-2, and SFU-3) is relative to the last dose of study treatment (+4, +8, and', '+22 weeks, respectively).', 'Amendment 2: 06 March 2019', '56', 'Confidential']\n\n###\n\n", "completion": "END"}